Mumps Vaccine Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Mumps Vaccine Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Mumps Vaccine Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxx6.12%
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

As per Analysis, the Paediatric segment leading the Mumps Vaccine market. Due to the increasing number of patients with infectious diseases like measles and mumps and the rise in research activities pertaining to paediatric vaccines, the paediatric segment held the largest proportion of the mumps vaccines market share and anticipated to continue to do so throughout the forecast period. Adult Paediatric

Adult Mumps Vaccine Market Analysis
XX
Adult Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Paediatric Mumps Vaccine Market Analysis
XX
Paediatric Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Mumps Vaccine Industry News

June 2022, GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older

August 2021, MMR vaccines for children help to protect front line from covid-19

In order to determine whether the MMR vaccine for children could protect front-line medical personnel from the Covid-19 virus or minimise the severity of the illness for those who get it, researchers from South Africa initiated a clinical experiment. The trials were launched by researchers from the Universities of the Witwatersrand (UW) and Cape Town (UCT) in South Africa.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Sanofi SA••• ••• ••• •••
Pfizer••• ••• ••• •••
AstraZeneca••• ••• ••• •••
Johnson & Johnson••• ••• ••• •••
GlaxoSmithKline••• ••• ••• •••
Novartis••• ••• ••• •••
CSL limited••• ••• ••• •••
VBI Vaccines••• ••• ••• •••
Bharat Biotech••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

As per Cognitive Market Research's latest published report, the Global Mumps Vaccine market size was USD 2.15 Billion in 2022 and it is forecasted to reach USD 3.46 Billion by 2030. Mumps Vaccine Industry's Compound Annual Growth Rate will be 6.12 % from 2023 to 2030.

Introduction of Mumps Vaccine

Mumps viruses are infectious. A fever, headache, muscle aches, feeling worn out and loss of appetite are frequently the first symptoms. The majority of patients then have salivary gland oedema. The sensitive, swelling jaw and puffed-up cheeks are the result of it. The Mumps is often a benign condition. However, it can result in severe, long-lasting issues, such as encephalitis, orchitis in males, oophoritis and mastitis in females. The mumps vaccines are also called MMR vaccines, which protect against measles, mumps, and rubella. Children typically receive the first dose between the ages of 9 and 15 months, followed by the second dose between the ages of 15 and 6 years, with a Minimum of four weeks in between each dose. Increasing research for combination vaccines and increasing infection are prime drivers of the market.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Mumps Vaccine Market Analysis is witnessing significant growth in the near future.

In 2023, the Adult segment accounted for a notable share of the Mumps Vaccine Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

The mumps vaccines are also called MMR vaccines, which protect against measles, mumps, and rubella. Children typically receive the first dose between the ages of 9 and 15 months, followed by the second dose between the ages of 15 and 6 years, with a Minimum of four weeks in between each dose.
The Mumps vaccine market is valued at USD 48.8 billion in 2022 and will be USD 35.8 billion by 2030 with a CAGR of 1.9% during the forecast period.
The players included Sanofi SA, Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Novartis, CSL limited, VBI Vaccines, Bharat Biotech.
Increasing research for combination vaccines and increasing infection are prime drivers of the market.
Yes, the report includes a COVID-19 impact analysis.
North America is anticipated to be the leading region in this market

★ Reviews

Rate this report

Mumps Vaccine Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Age TypeAdult, Paediatric
Distribution channelHospital & Clinic, Vaccination Centres
List of CompetitorsSanofi SA, Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Novartis, CSL limited, VBI Vaccines, Bharat Biotech

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Mumps Vaccine Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Sanofi SA
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Pfizer
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 AstraZeneca
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Johnson & Johnson
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 GlaxoSmithKline
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Novartis
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 CSL limited
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 VBI Vaccines
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Bharat Biotech
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis

  • Chapter 2. Global Mumps Vaccine Market Analysis

    • 2.1 Global Mumps Vaccine Market Analysis
    • 2.2 Global Mumps Vaccine Market Analysis by Region
    • 2.3 Global Mumps Vaccine Market Analysis by Age Type
    • 2.4 Global Mumps Vaccine Market Analysis by Distribution channel
    • 2.5 Global Mumps Vaccine Market Analysis by Key Players

  • Chapter 3. North America Mumps Vaccine Market Analysis

    • 3.1 North America Mumps Vaccine Market Analysis
    • 3.2 North America Mumps Vaccine Market Analysis by Country
    • 3.3 North America Mumps Vaccine Market Analysis by Age Type
    • 3.4 North America Mumps Vaccine Market Analysis by Distribution channel
    • 3.5 North America Mumps Vaccine Market Analysis by Key Players

  • Chapter 4. Europe Mumps Vaccine Market Analysis

    • 4.1 Europe Mumps Vaccine Market Analysis
    • 4.2 Europe Mumps Vaccine Market Analysis by Country
    • 4.3 Europe Mumps Vaccine Market Analysis by Age Type
    • 4.4 Europe Mumps Vaccine Market Analysis by Distribution channel
    • 4.5 Europe Mumps Vaccine Market Analysis by Key Players

  • Chapter 5. Asia Pacific Mumps Vaccine Market Analysis

    • 5.1 Asia Pacific Mumps Vaccine Market Analysis
    • 5.2 Asia Pacific Mumps Vaccine Market Analysis by Country
    • 5.3 Asia Pacific Mumps Vaccine Market Analysis by Age Type
    • 5.4 Asia Pacific Mumps Vaccine Market Analysis by Distribution channel
    • 5.5 Asia Pacific Mumps Vaccine Market Analysis by Key Players

  • Chapter 6. South America Mumps Vaccine Market Analysis

    • 6.1 South America Mumps Vaccine Market Analysis
    • 6.2 South America Mumps Vaccine Market Analysis by Country
    • 6.3 South America Mumps Vaccine Market Analysis by Age Type
    • 6.4 South America Mumps Vaccine Market Analysis by Distribution channel
    • 6.5 South America Mumps Vaccine Market Analysis by Key Players

  • Chapter 7. Middle East Mumps Vaccine Market Analysis

    • 7.1 Middle East Mumps Vaccine Market Analysis
    • 7.2 Middle East Mumps Vaccine Market Analysis by Country
    • 7.3 Middle East Mumps Vaccine Market Analysis by Age Type
    • 7.4 Middle East Mumps Vaccine Market Analysis by Distribution channel
    • 7.5 Middle East Mumps Vaccine Market Analysis by Key Players

  • Chapter 8. Africa Mumps Vaccine Market Analysis

    • 8.1 Africa Mumps Vaccine Market Analysis
    • 8.2 Africa Mumps Vaccine Market Analysis by Country
    • 8.3 Africa Mumps Vaccine Market Analysis by Age Type
    • 8.4 Africa Mumps Vaccine Market Analysis by Distribution channel
    • 8.5 Africa Mumps Vaccine Market Analysis by Key Players

  • Chapter 9. Age Type Analysis

    • 9.1 Adult
      • 9.1.1 Global Adult Market
      • 9.1.2 Global Adult Market by Region
    • 9.2 Paediatric
      • 9.2.1 Global Paediatric Market
      • 9.2.2 Global Paediatric Market by Region

  • Chapter 10. Distribution channel Analysis

    • 10.1 Hospital & Clinic
      • 10.1.1 Global Hospital & Clinic Market
      • 10.1.2 Global Hospital & Clinic Market by Region
    • 10.2 Vaccination Centres
      • 10.2.1 Global Vaccination Centres Market
      • 10.2.2 Global Vaccination Centres Market by Region

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 PESTEL Analysis
      • 11.8.1 Political Factors
      • 11.8.2 Economic Factors
      • 11.8.3 Social Factors
      • 11.8.4 Technological Factors
      • 11.8.5 Legal Factors
      • 11.8.6 Environmental Factors
    • 11.9 Industrial Chain Analysis (Subject to Data Availability)
      • 11.9.1 Industry Chain Analysis
      • 11.9.2 Manufacturing Cost Analysis
      • 11.9.3 Supply Side Analysis
        • 11.9.3.1 Raw Material Analysis
        • 11.9.3.2 Raw Material Procurement Analysis
        • 11.9.3.3 Raw Material Price Trend Analysis
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Bargaining Power of Suppliers
      • 11.10.2 Bargaining Power of Buyers
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Threat of Substitutes
      • 11.10.5 Degree of Competition
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. TOP 10 Country Analysis

    • 12.1 Country 1
    • 12.2 Country 2
    • 12.3 Country 3
    • 12.4 Country 4
    • 12.5 Country 5
    • 12.6 Country 6
    • 12.7 Country 7
    • 12.8 Country 8
    • 12.9 Country 9
    • 12.10 Country 10

  • Chapter 13. Research Findings

    • 13.1 Key Takeaways
    • 13.2 Analyst Point of View
    • 13.3 Assumptions and Acronyms

  • Chapter 14. Research Methodology and Sources

    • 14.1 Primary Data Collection
      • 14.1.1 Steps for Primary Data Collection
        • 14.1.1.1 Identification of KOL
      • 14.1.2 Backward Integration
      • 14.1.3 Forward Integration
      • 14.1.4 How Primary Research Help Us
      • 14.1.5 Modes of Primary Research
    • 14.2 Secondary Research
      • 14.2.1 How Secondary Research Help Us
      • 14.2.2 Sources of Secondary Research
    • 14.3 Data Validation
      • 14.3.1 Data Triangulation
    • 14.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Mumps Vaccine Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 9+
Forecast Accuracy (Historical) 94.2%
Report Pages 250+
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest Articles about Mumps Vaccine Market

Sources from the Pharma & Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Mumps Vaccine Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the mumps vaccine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report (250+ pages)
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.